Digene Stock Rises on Cancer-Test Results

Article excerpt

Byline: Marguerite Higgins, THE WASHINGTON TIMES

Shares of Digene Corp. surged last week after a German study supported the use of the Gaithersburg biotechnology company's screening test for cervical cancer.

Digene stock closed at $23.60 Friday on Nasdaq, climbing 9 percent from a week earlier at $21.72. The study was published in the British Journal of Cancer on Tuesday. The markets were closed yesterday in observance of Memorial Day.

The study of 8,101 women 30 or older found that Digene's diagnostic test for human papillomavirus (HPV), which is considered the main cause of cervical cancer, was 100 percent effective in detecting cervical cancer when applied with a Pap smear.

The confirmation of the HPV test's success opens up a huge market, with millions of annual checkups by American women.

Digene President Charles Fleischman said the study was "one more brick in the wall" of building the HPV test, which is the only one of its kind approved by the Food and Drug Administration.

"Each piece of information that comes out confirming our product's value propels us further in the market," Mr. Fleischman said.

Sales of the HPV test rose 45 percent in Digene's third fiscal quarter ended March 31 to $16.9 million from $11.6 million a year earlier, narrowing the company's losses to $619,381 (3 cents per share) from $3.3 million (19 cents) a year ago.

Mr. Fleischman projected revenue at the end of fiscal 2003, which ends June 30, to hit $62 million, with losses at $4.6 million. The company is forecasting revenue of $85 million and first-ever profits of $6.5 million (35 cents) in fiscal 2004.

While Digene focuses primarily on marketing the HPV test, the company plans to further develop tests for gonorrhea, chlamydia and Hepatitis B, Mr. Fleischman said.

Several biotech analysts said Digene's virtual monopolization in the HPV-screening market would last for at least the next three years until competitors such as Roche Diagnostics and Cytyc Corp. …